Pinealon: What It Is, Research & Safety (2026)

Pinealon is a synthetic tripeptide, Glu-Asp-Arg (EDR), from the Khavinson family of "peptide bioregulators", studied mainly for protecting brain cells against oxidative stress. The published evidence is mostly cell-culture and rat studies from the group that developed it. Its developers describe human memory benefits, but no independent, randomized human trial has been published. Pinealon is not FDA-approved and is not on the 503A Bulks List.

This article covers what Pinealon is, what the research actually measured, what is unknown about safety, and its regulatory position as of October 2026.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Pinealon at a Glance

What Is Pinealon?

Pinealon belongs to the short-peptide bioregulators developed by Vladimir Khavinson's group. The group's broader program, which also produced Testagen (covered for female patients in peptide bioregulators and women's hormone health), proposes that tiny peptides of two to four amino acids act as tissue-specific signals. Pinealon is the bioregulator linked to the brain.

Despite the name, Pinealon is not the pineal-gland peptide. That is Epitalon (Ala-Glu-Asp-Gly), which has a separate evidence base and a separate regulatory history.

What the Research Shows

Cell studies: oxidative stress and cell survival

The key English-language paper is a 2011 study in Rejuvenation Research. Pinealon limited the build-up of reactive oxygen species in rat cerebellar granule cells, neutrophils, and PC12 (pheochromocytoma) cells exposed to oxidative stress, and it reduced necrotic cell death [1]. The effect depended on concentration. The authors noted that the antioxidant effect leveled off at lower concentrations while effects on the cell cycle continued at higher ones. From this they argued that Pinealon may interact directly with the cell genome as well as acting as an antioxidant [1].

Evidence level: in vitro.

Animal studies: prenatal hyperhomocysteinemia

In a 2012 rat study, pregnant rats were fed a methionine-loaded diet to raise homocysteine. Offspring of mothers given Pinealon showed better spatial orientation and learning, and their cerebellar neurons were more resistant to oxidative stress, than offspring of untreated mothers [2].

Evidence level: animal (rat), single study from the developing group.

Nuclear entry and DNA binding

Fluorescently labeled Pinealon entered the cytoplasm, nucleus and nucleolus of HeLa cells. In cell-free experiments it changed the fluorescence of DNA fragments in a sequence-dependent way [3]. These observations support the developers' idea that short peptides can reach DNA. They do not show a clinical effect.

Evidence level: in vitro.

Proposed gene-expression mechanism

A 2020 review by Khavinson and colleagues proposes that EDR binds histones and/or nucleic acids and influences MAPK/ERK signaling, apoptosis proteins (caspase-3, p53), antioxidant enzymes (SOD2, GPX1), and other proteins involved in Alzheimer's disease [4]. The review's framing is cautious: the peptide "is assumed to" act this way. This is a mechanistic hypothesis assembled from cell, animal and modeling work.

Human data

The 2020 review states that EDR "improves memory issues in elderly patients" [4]. A Russian-language review from the same group compares short neuroprotective peptides with polypeptide brain extracts in people of different ages [5]. We could not find a randomized, placebo-controlled human trial of Pinealon in an indexed journal, and we found no independent replication outside the developers' network.

Evidence level for human benefit: low. It rests on reports from the developing group.

How Strong Is the Pinealon Evidence?

• Small, single-group literature. Nearly every study comes from Khavinson's institute and its collaborators [6].
• Surrogate endpoints. Cell survival, reactive oxygen species and rodent maze performance are early markers. None of them is a patient outcome.
• No pharmacokinetic data. We found no published human data on Pinealon's absorption, distribution, or half-life. That makes it hard to judge whether concentrations that were active in cell culture are reached in the brain.
• Product variability. Products sold as Pinealon are not standardized.

Safety Considerations

There is no systematic human safety data for Pinealon. The cell and rat studies above were not designed to measure toxicity. Points prescribers should weigh:

• Unknown adverse-event profile. Absence of reported harm in small developer studies is not evidence of safety.
• Theoretical proliferation concern. The 2011 study reported effects on proliferative processes and the cell cycle [1]. That is a reason for caution in patients with active or recent malignancy until more is known.
• Quality. Research-chemical products carry no assurance of identity, purity, sterility, or endotoxin limits.
• Special populations. No data in pregnancy, breastfeeding, or children.
• Interactions. No interaction studies exist.

Regulatory Status (October 2026)

Pinealon is not FDA-approved for any use and is not on the 503A Bulks List. It was not among the peptides considered at FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. That meeting voted to recommend Epitalon (7–4, 1 abstention) and several others, but those votes are advisory and rulemaking is pending. In the U.S., Pinealon is mainly sold as a "research use only" chemical or as an imported oral product. Neither channel involves FDA review.

Check the FDA Peptide Status Tracker for current information.

Where Pinealon Fits

For clinicians, Pinealon is best treated as a research-stage compound: it has interesting preclinical signals for neuroprotection but no established human efficacy, safety, or pharmacokinetics. Patients who ask about it for memory or "brain aging" should hear that the evidence is preliminary and comes largely from one research group.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A partner pharmacies covering all 50 states and D.C.; prescribers can start at For Providers.

Frequently Asked Questions

What is Pinealon?

Pinealon is a synthetic tripeptide, Glu-Asp-Arg, developed by Vladimir Khavinson's group in St. Petersburg as a "bioregulator" for the brain. It has been studied in cell culture and rats for protection against oxidative stress.

Is Pinealon the same as Epitalon?

No. Epitalon is a different peptide (Ala-Glu-Asp-Gly) associated with the pineal gland. Pinealon is a tripeptide linked to the brain. They have separate research records and separate regulatory status.

Does Pinealon improve memory?

Its developers report memory improvements in elderly patients, but we could not find a randomized, placebo-controlled human trial in an indexed journal. The best published evidence is from cell and rat studies.

Is Pinealon safe?

Its human safety has not been systematically studied. There are no published pharmacokinetic, interaction, or long-term safety data, and product quality outside regulated pharmacies is not assured.

Is Pinealon FDA-approved or legal to compound?

Pinealon is not FDA-approved and is not on the 503A Bulks List. It was not reviewed at the July 2026 PCAC meeting. Check the FDA Peptide Status Tracker for updates.

References

1. Khavinson V, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011;14(5):535-541. PubMed
2. Arutjunyan A, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012;5(2):179-185. PubMed
3. Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. PubMed
4. Khavinson V, et al. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 2020;26(1):159. PubMed
5. Umnov RS, et al. Neuroprotective effects of peptides bioregulators in people of various age [in Russian]. Adv Gerontol. 2013;26(4):671-678. PubMed
6. Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PubMed